A 26 week randomised, parallel three-arm, open-label, multi-centre, multinational treat-to-target trial comparing fixed ratio combination of insulin degludec and liraglutide versus insulin degludec or liraglutide alone, in subjects with type 2 diabetes treated with 1-2 oral anti-diabetic drugs (OADs) with a 26 week extension

Trial Profile

A 26 week randomised, parallel three-arm, open-label, multi-centre, multinational treat-to-target trial comparing fixed ratio combination of insulin degludec and liraglutide versus insulin degludec or liraglutide alone, in subjects with type 2 diabetes treated with 1-2 oral anti-diabetic drugs (OADs) with a 26 week extension

Completed
Phase of Trial: Phase III

Latest Information Update: 26 Jun 2018

At a glance

  • Drugs Insulin degludec/liraglutide (Primary) ; Insulin degludec; Liraglutide
  • Indications Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms DUAL-I
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 26 Jun 2018 Results of post-hoc analysis from (DUAL I-V and VII), were presented at the 78th Annual Scientific Sessions of the American Diabetes Association.
    • 26 Jun 2018 Results of pooled data from DUAL I, II,V and VII, were presented at the 78th Annual Scientific Sessions of the American Diabetes Association.
    • 09 Dec 2017 Results of an analysis comparing the results of the LixiLan and DUAL clinical development programmes, presented at the 40th Annual San Antonio Breast Cancer Symposium
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top